Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Elixiron Immunotherapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo

Details:

Proceeds will be used to advance phase 1 trials of two pipeline candidates, EI-1071 and EI-001 and take three immuno-oncology assets towards IND applications .

Lead Product(s): EI-1071

Therapeutic Area: Neurology Product Name: EI-1071

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Pangu Capital

Deal Size: $27.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing August 23, 2021

ASK
US

Upload
your Pipeline Activity

Elixiron Immunotherapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Elixiron Immunotherapeutics Awarded Alzheimer's Association Grant to Target Microglia in Alzheimer's Disease

Details:

Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.

Lead Product(s): EI1071

Therapeutic Area: Neurology Product Name: EI1071

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Alzheimer's Association

Deal Size: $1.0 million Upfront Cash: Undisclosed

Deal Type: Funding August 26, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY